Mechanical Technology, Incorporated Announces Third Quarter 2020 Financial Results

PR Newswire

ALBANY, N.Y., Nov. 12, 2020 /PRNewswire/ — Mechanical Technology, Incorporated (“MTI” or the “Company”), a publicly traded company (OTC Pink: MKTY) headquartered in Albany, New York, announced its second quarter financial results for 2020. Please visit https://www.mechtech.com under News. 

For the third quarter 2020, net income was $1.5 million, bringing the year to date total net income to $1.97 million which represents a year over year increase of 352% year to date.

The financial performance is a result of the MTI Instrument subsidiary successfully delivering on the United States Air Force historic contract. The aforementioned increase in revenue combined with an improvement in product margin of 378 basis has contributed to the improvement in operating income.

MTI subsidiary EcoChain, Inc., has successfully ramped up capacity and is trending favorably, revenues were $176k for the current quarter, an increase of 252% over the prior quarter. EcoChain, Inc. is continuing to invest in mining purchases to reach facility capacity, estimated to be in November 2020.

About MTI
MTI is the parent company of MTI Instruments, Inc. and EcoChain, Inc. Through MTI Instruments, MTI is engaged in the design, manufacture and sale of test and measurement instruments and systems that use a comprehensive array of technologies to solve complex, real world applications in numerous industries, including manufacturing, electronics, semiconductor, solar, commercial and military aviation, automotive and data storage. Through EcoChain, MTI is developing cryptocurrency mining facilities powered by renewable energy that integrate with the bitcoin blockchain network. For more information about MTI, please visit https://www.mechtech.com.

Statements in this press release that are not historical fact and in particular, with respect to future growth opportunities and continued investments in innovation, constitute forward-looking statements involving risks, uncertainties, estimates, and assumptions that may cause our actual results, performance, or achievements to be materially different from those expressed or implied by forward-looking statements. Such forward-looking statements are made as of today, and MTI disclaims any duty to update such statements. Factors that could cause anticipated results not to occur include, but are not limited to: general economic conditions and the uncertainty of the U.S. and global economy, particularly in light of the COVID-19 pandemic; our inability to develop and utilize new technologies that address the needs of our customers and otherwise keep pace with technological developments; the loss of services of one or more of our key employees or the inability to hire, train, and retain key personnel; the dependence of our business on a small number of customers and potential loss of government contracts
; our inability to build and maintain relationships with our customers; and changes in national and global economic or other conditions that impact demand for our products and/or accelerated purchases of our products by our customers due to changes in their business needs.

For more information about the Company, please visit https://www.mechtech.com.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/mechanical-technology-incorporated-announces-third-quarter-2020-financial-results-301172008.html

SOURCE Mechanical Technology, Incorporated

FOUR MINORITY OWNED SUPPLIERS OF THE YEAR ARE SELECTED AND RECOGNIZED BY NMSDC FOR THEIR PURSUIT OF EXCELLENCE IN PROVIDING SUPPLY CHAIN SOLUTIONS TO CORPORATE PARTNERS

New York City, New York, Nov. 12, 2020 (GLOBE NEWSWIRE) — National Minority Supplier Development Council (NMSDC) President and CEO, Adrienne Trimble, is exuberant about the tremendous success of the organization’s annual national conference this week, through a 100% virtual platform. “While we were not together face-to-face,” she notes, “All attendees had access to the same – and perhaps even more – high-caliber speakers, learning sessions, and networking opportunities they’ve come to expect from NMSDC. Just through a different platform.”  NMSDC’s 2020 National Conference + Business Opportunity Exchange was held 100% online from October 26-29, 2020.

 

NMSDC’s commitment to advance minority business economic inclusion is reflected in the event’s “In This Together” theme and reinforced by sessions featuring speakers with expert insight about how to pivot during today’s extraordinarily challenging conditions. The NMSDC Annual Conference + Business Opportunity Exchange is the nation’s largest forum for minority supplier development, with a 48-year history of attracting thousands of corporate executives, minority business owners, and government officials each year.

 

Trimble stated, “Now more than ever, our Corporate Partners and MBEs need us to push forward and find new ways to get around every obstacle. NMSDC, our 23 affiliate Regional Councils throughout the United States, five international partners and the Business Consortium Fund (BCF) represent an oasis of support for MBEs through our mission to certify, develop, connect, and advocate for their economic sustainability.”

 

NMSDC embraced new technologies that enabled the organization to accomplish their objectives without sacrificing quality, service, or health. The 100% virtual conference platform showcased those changes – from vibrant sessions and informative workshops to an awards celebration and lively entertainment. By introducing a virtual version of their Business Opportunity Exchange component of the conference – corporations and MBEs again made meaningful connections and continued to build their professional networks.

 

This has been an incredibly difficult year for all MBEs and despite the impact of three pandemics (COVID-19, racial discrimination and social unrest, and a Recession), NMSDC moved forward aggressively and pivoted because it was necessary for the survival of MBEs. We are providing sustainable economic solutions to the racial injustice, institutionalized racism and injuries which Black people have suffered in America.  “Statements are great, but they need to be backed by real actions that are going to address how minority businesses are going to compete for contracts on an ongoing basis,” Trimble said. “Until you understand what the real problem is, you can’t solve it.”

 

For Trimble, the case is not about just doing social good but of driving transformative economic prosperity through capitalism. When companies hire minority-owned suppliers, which tend to hire more workers of color, they are creating jobs in forgotten communities and helping to provide disposable income to people who can, in turn, afford to buy their goods and services.  A close examination of wealth in the U.S. finds evidence of staggering racial disparities.  The most sustainable solution to accelerate the elimination of this wealth gap is to increase the number and success of minority owned businesses; her goal is to close the ethnic wealth disparities. 

 

SUPPLIER OF THE YEAR

 

Each year, at the national annual conference, NMSDC presents its prestigious “Supplier of the Year” Awards to recognize a select number of certified minority business enterprise (MBE) and their exemplary achievements in providing solutions to our corporate partners.  This award is regarded as the most significant honor to an MBE because it recognizes Asian, Black, Hispanic and Native American business enterprises for their business growth and development, operational success, support of other minority businesses and active participation in the community. The honorees are divided into four categories, based on annual revenues.  One company from each class is named National Supplier of the Year.  These suppliers have made it through this disruptive year and have continued their unwavering support to corporate America despite these voluminous challenges. 

 

Class I: Firm with less than $1 million in annual revenue – National Winner: Twice Media Productions, LLC  

 

Class II: Firm with $1 million to $10 million in annual revenue – National Winner: The JPI Group, LLC

 

Class III: Firm with $10 million to $50 million in annual revenue – National Winner: United Mechanical and Metal Fabricators Inc.

 

Class IV: Firm with more than $50 million in annual revenue – National Winner: ActOne Group (The Act 1 Group, Inc.)

 

About NMSDC | nmsdc.org

Chartered in 1972, The National Minority Supplier Development Council (NMSDC) was stood up because of the civil rights movement in the late 1960s and continues to be the leading minority business development organization in the United States. NMSDC supports the economic sustainability of more than 12,000 certified minority business enterprises (MBEs) and advances minority business development by facilitating procurement opportunities between its certified MBEs and its network of Corporate Members.  The NMSDC network includes a National Office in New York, 23 affiliate regional councils, five international partner organizations and the Business Consortium Fund (BCF) as its funding arm.

 

Tammy Wilkins
National Minority Supplier Development Council, Inc.
212-944-2430
[email protected]

Astrotech Reports First Quarter of Fiscal Year 2021 Financial Results

Astrotech Reports First Quarter of Fiscal Year 2021 Financial Results

AUSTIN, Texas–(BUSINESS WIRE)–
Astrotech Corporation (NASDAQ: ASTC) reported its financial results for the first quarter of fiscal year 2021, which ended September 30, 2020.

In October, we completed two strategic capital raises for a total of $24.2 million, strengthening our balance sheet for our future growth. The financings allow for continued operating expenses and working capital as we increase sales of our TRACER 1000™ explosives trace detector (ETD) to DHL (Deutsche Post AG) and other customers in the security market, launch the AgLAB-1000-D2™ into the hemp and cannabis industry, and develop, in partnership with Cleveland Clinic, the BreathTest-1000™ to screen for volatile organic compound (VOC) metabolites found in a person’s breath that could indicate they may have an infection, including Coronavirus Disease 2019 (“COVID-19”) or the resulting disease, pneumonia.

In September, we announced the completion of non-detection testing with the US Transportation Security Administration (TSA), an important milestone that positions us well for detection testing, which is the final phase of TSA’s Air Cargo Screening Technology Qualification Test (ACSQT). Once detection testing is completed successfully, we understand that the TRACER 1000™ will be listed on the Air Cargo Screening Technology List (ACSTL) as an “approved” device and thereby approved for cargo sales in the United States. We also announced that we surpassed $1 million in purchase orders of our TRACER 1000 with an additional $1 million in future service and support commitments as we look to continue to gain market share in the domestic and international ETD markets.

“We are excited to have passed the $1 million milestone for our TRACER 1000 in October. We believe we offer the most advanced ETD on the market and we are excited to be nearing completion of detection testing with the TSA,” stated Thomas B. Pickens III, Chairman and Chief Executive Officer of Astrotech Corporation. “We are also thrilled to have entered into a partnership between BreathTech and Cleveland Clinic, one of the world’s leading breath analysis institutions. Dr. Dweik and his colleagues at Cleveland Clinic have successfully led many clinical trials applying mass spectrometry to identify unique metabolites using breath samples. We believe that our technology has the potential to play an important role in providing a quick, non-invasive, easy-to-use screening device that can be utilized in numerous locations including hospitals, nursing homes, schools, and airports as we look to get all of our lives back to normal again.”

First Quarter Fiscal Year 2021 Financial Highlights

Management continues efforts to optimize our resources while reducing cost and adding financial flexibility.

  • Commercial sales of the TRACER 1000 continued, leading to revenue of $140 thousand for the first quarter of fiscal 2021. Additional purchase orders have already been received.
  • SG&A expenses decreased $276 thousand, or 23.0%, and R&D expenses decreased $246 thousand, or 28.8%.
  • Monthly cash outlay for this fiscal year has been reduced to approximately $493 thousand, a 19.1% reduction from our cash outlay through the first three months of fiscal year 2020.
  • The Company terminated its corporate office lease in Austin, Texas, resulting in net cash savings of approximately $870 thousand over the next three years.

About Astrotech

Astrotech (NASDAQ: ASTC) is a science and technology development and commercialization company that launches, manages, and builds scalable companies based on innovative technology in order to maximize shareholder value. 1st Detect develops, manufactures, and sells trace detectors for use in the security and detection market. AgLAB is developing chemical analyzers for use in the agriculture market. BreathTech is developing a breath analysis tool to provide early detection of lung diseases. Astrotech is headquartered in Austin, Texas. For information, please visit www.astrotechcorp.com.

About AgLAB-1000™ and BreathTest-1000™

This press release contains information about our new products under development, AgLAB-1000 and BreathTest-1000. Product development involves a high degree of risk and uncertainty, and there can be no assurance that our new products will be successfully developed, achieve their intended benefits, receive full market authorization, or be commercially successful. In addition, FDA approval will be required to market BreathTest-1000 in the United States. Obtaining FDA approval is a complex and lengthy process, and there can be no assurance that FDA approval for BreathTest-1000 will be granted on a timely basis or at all.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These factors include, but are not limited to, the severity and duration of the COVID-19 pandemic and its impact on the U.S. and worldwide economy, the timing, scope and effect of further U.S. and international governmental, regulatory, fiscal, monetary and public health responses to the COVID-19 pandemic, the Company’s use of proceeds from the common stock offerings, whether we can successfully complete the development of our new products and proprietary technologies, whether we can obtain the FDA and other regulatory approvals required to market our products under development in the United States or abroad, and whether the market will accept our products and services, as well as other risk factors and business considerations described in the Company’s Securities and Exchange Commission filings including the annual report on Form 10-K. Any forward-looking statements in this document should be evaluated in light of these important risk factors. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company assumes no obligation to update these forward-looking statements.

 

ASTROTECH CORPORATION

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except per share data)

(Unaudited)

 

 

 

Three Months Ended

September 30,

 

 

 

2020

 

 

2019

 

Revenue

 

$

140

 

 

$

1

 

Cost of revenue

 

 

113

 

 

 

 

Gross profit

 

 

27

 

 

 

1

 

Operating expenses:

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

926

 

 

 

1,202

 

Research and development

 

 

609

 

 

 

855

 

Disposal of corporate lease

 

 

544

 

 

 

 

Total operating expenses

 

 

2,079

 

 

 

2,057

 

Loss from operations

 

 

(2,052

)

 

 

(2,056

)

Interest and other expense, net

 

 

(59

)

 

 

(12

)

Loss from operations before income taxes

 

 

(2,111

)

 

 

(2,068

)

Income tax benefit

 

 

 

 

 

 

Net loss

 

$

(2,111

)

 

$

(2,068

)

Weighted average common shares outstanding:

 

 

 

 

 

 

 

 

Basic and diluted

 

 

7,719

 

 

 

5,591

 

Basic and diluted net loss per common share:

 

 

 

 

 

 

 

 

Net loss

 

$

(0.27

)

 

$

(0.37

)

Total comprehensive loss

 

$

(2,111

)

 

$

(2,068

)

 

ASTROTECH CORPORATION

Condensed Consolidated Balance Sheets

(In thousands, except share and per share data)

 

 

 

September 30,

2020

 

 

June 30,

2020

 

Assets

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

1,853

 

 

$

3,349

 

Accounts receivable

 

 

52

 

 

 

101

 

Inventory:

 

 

 

 

 

 

 

 

Raw materials

 

 

114

 

 

 

416

 

Work-in-process

 

 

337

 

 

 

38

 

Finished goods

 

 

161

 

 

 

222

 

Income tax receivable

 

 

 

 

 

429

 

Prepaid expenses and other current assets

 

 

283

 

 

 

117

 

Total current assets

 

 

2,800

 

 

 

4,672

 

Property and equipment, net

 

 

100

 

 

 

99

 

Assets held for disposal

 

 

 

 

 

237

 

Operating leases, right-of-use assets, net

 

 

287

 

 

 

851

 

Other assets

 

 

 

 

 

71

 

Total assets

 

$

3,187

 

 

$

5,930

 

Liabilities and stockholders’ equity (deficit)

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Accounts payable

 

 

75

 

 

 

239

 

Payroll related accruals

 

 

473

 

 

 

433

 

Accrued expenses and other liabilities

 

 

676

 

 

 

627

 

Income tax payable

 

 

2

 

 

 

2

 

Term note payable – related party

 

 

2,500

 

 

 

2,500

 

Term note payable

 

 

330

 

 

 

210

 

Lease liabilities

 

 

198

 

 

 

339

 

Total current liabilities

 

 

4,254

 

 

 

4,350

 

Term note payable, net of current portion

 

 

211

 

 

 

332

 

Lease liabilities, net of current portion

 

 

166

 

 

 

623

 

Other liabilities

 

 

 

 

 

 

Total liabilities

 

 

4,631

 

 

 

5,305

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Stockholders’ equity (deficit)

 

 

 

 

 

 

 

 

Convertible preferred stock, $0.001 par value, 2,500,000 shares authorized; 280,898 shares of Series D issued and outstanding at September 30, 2020 and June 30, 2020

 

 

 

 

 

 

Common stock, $0.001 par value, 50,000,000 shares authorized; 8,243,686 and 8,250,286 shares issued at September 30, 2020 and June 30, 2020, respectively; 7,843,770 and 7,850,362 shares outstanding at September 30, 2020 and June 30, 2020, respectively

 

 

190,599

 

 

 

190,599

 

Treasury stock, 399,916 shares at cost at September 30, 2020 and June 30, 2020

 

 

(4,129

)

 

 

(4,129

)

Additional paid-in capital

 

 

13,976

 

 

 

13,934

 

Accumulated deficit

 

 

(201,890

)

 

 

(199,779

)

Total stockholders’ equity (deficit)

 

 

(1,444

)

 

 

625

 

Total liabilities and stockholders’ equity (deficit)

 

$

3,187

 

 

$

5,930

 

 

Eric Stober, Chief Financial Officer, Astrotech Corporation, (512) 485-9530

 

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Medical Devices Health Technology Agriculture Natural Resources Hardware

MEDIA:

Logo
Logo

Beantown Throwdown Goes Virtual: Region’s Top Multi-University Start-up Pitch Competition Slated for November 18

As part of Global Entrepreneur Week, MIT Enterprise Forum Cambridge hosts collegiate entrepreneurs battling for title of Best Student Start-up

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) — College and university student entrepreneurs will soon battle for bragging rights and prizes during the 8th Annual Beantown Throwdown – focusing on markets ranging from digital healthcare and employment/staffing services to on-call delivery and personal grooming.

Hosted by MIT Enterprise Forum (MITEF) Cambridge and moving online this year, the region’s longest-standing and largest cross-college pitch-off competition will be held Wednesday, November 18, from 5:30-7 p.m. Registration and more information is available here.

Scheduled during Global Entrepreneur Week, the program features a representative from each team making a five-minute pitch, then responding to five minutes of questions from a judging panel with extensive experience in innovative technologies and business models. This year’s experts include:

The night will also include a fireside chat between Boston Globe Innovation Economy Columnist and Innovation Leader Co-founder Scott Kirsner and Rudina Seseri, founder and partner of Glasswing Ventures. With decades of experience advising, reporting on and investing in technology firms, the pair will share insights into some of the most important trends affecting entrepreneurs and their companies.

Given the virtual format and number of teams participating, the Beantown Throwdown this year will feature a two-part program – with half the teams pitching in the fall and the other half in the spring. The winning teams from the two sessions will then compete for top honors in a pitch-off to be held in the spring. Prizes will be awarded to all teams to help drive their entrepreneurial endeavors forward. More information will be made available at a later date.

For the fall session, contestants will include:

  • Babson College: Busy Boda – a mobile phone-based motorbike hailing app initially targeting Kenya
  • Boston College: Conditer – a patisserie where style meets the culinary arts
  • Brown University: Cress Health – digital technologies for wellness and mental health
  • MIT: Surge Employment Solutions – meeting human capital needs with formerly incarcerated people
  • Tufts University: Cogna Technology – the next revolution in sleep
  • Wentworth Institute of Technology: Watch the Krown – stylish and functional haircare products

“Early stage entrepreneurs can struggle to get visibility for their startups and to connect with potential investors, mentors and others who can help them succeed,” said MIT Enterprise Forum Cambridge Executive Director Katja Wald. “The pandemic has made that even more challenging. Additionally, most don’t get as many opportunities as they’d like to meet peers from other colleges and universities. Beantown Throwdown is designed to help overcome those obstacles while celebrating the creativity, vision and drive embodied in these student-run startups.”

The Beantown Throwdown is made possible by sponsors CHEN PR, Withum, Caldwell IP, Hamilton Brook Smith Reynolds and Morse. A limited number of sponsorship opportunities are still available; please contact Amy Goggins ([email protected] or 617-650-2562) at MITEF Cambridge for more information.

About the MIT Enterprise Forum Cambridge

The MIT Enterprise Forum Cambridge is the founding chapter and one of the worldwide chapters comprising the MIT Enterprise Forum, Inc.  We offer a range of programs and events for any entrepreneur, anywhere, to facilitate critical one-on-one mentoring while providing services that increase the skills and expertise necessary for startups to succeed. Check us out on Twitter, FacebookLinkedInYouTube or Spotify.

PRESS CONTACT:
Katja Wald
MIT Enterprise Forum Cambridge
[email protected]
(617) 253-8238 

Monopar Therapeutics Reports Third Quarter 2020 Financial Results and Business Update


Validive



®



Phase 2b/3 Clinical Trial on Track to Start Before Year-end



Issuance of New Patents For Validive



Camsirubicin Phase 2 Clinical Trial to Start Late 2020/Early 2021

WILMETTE, Ill., Nov. 12, 2020 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced third quarter 2020 financial results and business update.

Third Quarter Business Update


Lead Product Candidate Validive

  • Monopar’s Phase 2b/3 clinical trial of Validive (clonidine HCl mucobuccal tablet) for the prevention of severe oral mucositis (SOM) in patients undergoing chemoradiotherapy for oropharyngeal cancer (OPC) is on track to commence before year-end. There currently is no FDA-approved prevention or treatment for radiation-induced SOM.
  • The U.S. Patent and Trademark Office allowed patent claims for Monopar’s lead product candidate, Validive, covering “Clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of chemotherapy.” The recently issued patents would provide protection should Monopar determine in the future to conduct additional Validive development and commercialization activities related to adverse side effects of chemotherapy beyond OPC.


Camsirubicin

  • The Phase 2 clinical trial of camsirubicin is anticipated to begin at the end of 2020 or in early 2021. Monopar has partnered with Grupo Español de Investigación en Sarcomas (GEIS), which will lead the multi-country, randomized, open-label Phase 2 clinical trial evaluating camsirubicin head-to-head against standard-of-care doxorubicin in patients with advanced soft tissue sarcoma (ASTS).
  • The trial will begin with a dose escalation “run-in” prior to the randomization portion of the trial. The primary endpoint of the trial will be progression-free survival, with secondary endpoints including overall survival, response rate, and incidence of treatment-emergent adverse events.


MNPR-101

  • Forward progress was made on the Monopar/NorthStar collaboration focused on developing a novel treatment for severe COVID-19 by partnering with 1) IsoTherapeutics Group, LLC to develop and manufacture radioimmunotherapeutics targeting uPAR (uPRITs), 2) Aragen Bioscience, Inc. to perform studies aimed at selecting a lead candidate uPRIT to advance into IND-enabling development, and 3) The University of Texas Health Science Center at Tyler and its Texas Lung Injury Institute (TLII) to perform in vitro and in vivo studies through the TLII and to participate in the clinical development of uPRITs.

Third Quarter Summary Financial Results


Results for the Third Quarter Ended September 30, 2020 Compared to the Third Quarter Ended September 30, 2019


Cash and Net Loss

Cash and cash equivalents as of September 30, 2020 were $18.0 million, which includes $6.7 million of net proceeds raised in the third quarter of 2020 under the Company’s Capital on Demand® Sales Agreement with JonesTrading Institutional Services, at an average gross price per share of $9.66. Monopar anticipates that its current cash and cash equivalents will fund the Company’s planned operations through 2021, including the initiation and completion of the Phase 2b portion of its Validive clinical trial and the initiation of the Phase 3 portion, the funding of the initiation of the GEIS Phase 2 camsirubicin clinical trial, and continuation of the development of the COVID-19 uPRIT program. The Company will need to raise funds or engage a partner to complete the Validive Phase 3 clinical trial. Net loss for the third quarter of 2020 was $1.6 million or $0.15 per share compared to net loss of $0.7 million or $0.08 per share for the third quarter of 2019.


Research and Development (R&D) Expenses

R&D expenses for the third quarter of 2020 were $1.2 million, compared to $0.2 million, for the third quarter of 2019. This increase of $1.0 million is primarily attributed to increases in expenses for the planning of the camsirubicin Phase 2 clinical trial and manufacturing expenses of $0.4 million, increases in the Validive clinical trial planning and manufacturing expenses of $0.3 million, and increases in R&D personnel salaries and benefits, including equity grants and salaries and benefits for three new R&D personnel of $0.3 million.


General and Administrative (G&A) Expenses

G&A expenses for the third quarter of 2020 were $0.4 million, compared to $0.5 million, for the third quarter of 2019.

About Monopar Therapeutics

Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The Company’s pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; and a preclinical stage uPAR targeted antibody, MNPR-101, for advanced cancers and severe COVID-19. For more information, and links to SEC filings that contain detailed financial information, visit: https://ir.monopartx.com/quarterly-reports.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include statements concerning Monopar’s ability to commence its Phase 2b/3 clinical trial of Validive before the end of 2020, whether the recently issued patents would provide protection for development and commercialization in potential future indications, GEIS’s ability to begin the camsirubicin Phase 2 clinical trial at the end of 2020 or early 2021, whether the Monopar/NorthStar collaboration will be successful in developing a uPRIT to treat severe COVID-19 with its development partners and whether the Company’s current cash and cash equivalents will fund the Company’s planned operations through 2021. The forward-looking statements involve risks and uncertainties including, but not limited to, not commencing the Validive Phase 2b/3 clinical trial or the Phase 2 GEIS-sponsored camsirubicin clinical trial within expected timeframes, if at all, our ability to commence the Validive Phase 3 portion without additional fundraising or a development partnership, to raise sufficient funds or engage a partner to complete the Phase 3 clinical trial, and not successfully developing a COVID-19 uPRIT with the Company’s development collaborators. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Contact

Kim R. Tsuchimoto
Chief Financial Officer
[email protected]

Follow Monopar on social media for updates: 
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics

MTBC’s CareCloud Announces Growth-Focused Partnership with MDS Medical

SOMERSET, N.J, Nov. 12, 2020 (GLOBE NEWSWIRE) —

MTBC, Inc.
(Nasdaq: MTBC) (Nasdaq: MTBCP), a leading provider of cloud-based healthcare IT solutions and services, including telehealth, today announced that its MSO (management services organization) relationship between its CareCloud operating division and MDS Medical is helping accelerate market growth of CareCloud’s comprehensive electronic health records (EHR) solution and practice management (PM) software. MDS Medical is positioning CareCloud’s solutions in front of ambulatory physician groups and providing comprehensive technology, training, support, and revenue cycle management services for the CareCloud platform.

“MDS Medical only partners with the best EHR software vendors on the market and we are honored to be one of their preferred partners,” said Wes Stolp, Executive Vice President of Sales, MTBC. “Through MDS Medical’s campaign efforts, we have the opportunity to provide comprehensive EHR software to thousands of healthcare providers. We are excited to help even more practices successfully compete in today’s highly competitive landscape.”

As a CareCloud MSO, MDS Medical is positioning CareCloud’s robust EHR platform in front of small practices and large multi-specialty group physicians. This initiative will align CareCloud’s platform as an all-in-one solution for physician practices seeking to expedite encounters, drive profits, and improve clinical outcomes.

“Our partnership with CareCloud enables MDS clients to leverage the power of a modern and completely cloud-based EHR, while also retaining complete control and flexibility over revenue cycle management operations and staffing,” said Bill Schroeder, Chief Executive Officer, MDS Medical. “The CareCloud platform provides a powerful arsenal of enterprise-level tools that enable our medical practice clients to deliver an extraordinary patient experience while remaining independent and profitable in a value-based care environment.”

MDS Medical is actively marketing and campaigning CareCloud’s comprehensive platform to hundreds of MDS Medical clients and already successfully supporting 16 physician groups on the CareCloud platform. Additionally, MDS Medical is leveraging MTBC’s dedicated, on-demand workforce through MTBC Force.


Click here
to learn more about CareCloud’s cloud-based EHR software as part of MDS Medical’s managed services.

About MDS Medical

MDS Medical is a leading provider of healthcare technology and revenue cycle management solutions for physician practices and enterprise health systems across the United States. As a managed service organization (MSO) partner for the award-winning CareCloud and athenahealth, Inc. EHR platforms, MDS combines best-of-breed healthcare technology with a consultative service model that facilitates improved workflow efficiencies, enhanced patient safety and satisfaction, and stronger practice financial performance. MDS Medical’s expert team of EHR, revenue cycle management, and IT consultants work closely with our customers to build organizations that thrive in a value-based care environment.

Learn more by visiting www.mdsmed.com.

About MTBC

MTBC is a healthcare information technology company that provides a full suite of proprietary cloud-based solutions, together with related business services, to healthcare providers and hospitals throughout the United States. Our Software-as-a-Service (or SaaS) platform includes revenue cycle management (RCM), practice management (PM), electronic health record (EHR), business intelligence, telehealth and patient experience management (PXM) solutions for high-performance medical groups. MTBC helps clients increase financial and operational performance, streamline clinical workflows and make better business and clinical decisions, allowing them to improve patient care while reducing administrative burdens and operating costs. MTBC’s common stock trades on the Nasdaq Global Market under the ticker symbol “MTBC,” and its Series A Preferred Stock trades on the Nasdaq Global Market under the ticker symbol “MTBCP.”

For additional information, please visit our website at www.mtbc.com. To view MTBC’s latest investor presentation, read press releases, and listen to interviews with management, please visit ir.mtbc.com.

Follow MTBC on LinkedInTwitter and Facebook.

Forward Looking Statements

This press release contains various forward-looking statements within the meaning of the federal securities laws. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “might,” “will,” “should,” “intends,” “expects,” “plans,” “goals,” “projects,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of these terms or other comparable terminology.

Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. Forward-looking statements in this press release include, without limitation, statements reflecting management’s expectations for future financial performance and operating expenditures, expected growth, profitability and business outlook, the impact of the Covid-19 pandemic on our financial performance and business activities, and the expected results from the integration of our acquisitions.

These forward-looking statements are only predictions, are uncertain and involve substantial known and unknown risks, uncertainties and other factors which may cause our (or our industry’s) actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all of the risks and uncertainties that could have an impact on the forward-looking statements, including without limitation, risks and uncertainties relating to the Company’s ability to manage growth, migrate newly acquired customers and retain new and existing customers, maintain cost-effective global operations, increase operational efficiency and reduce operating costs, predict and properly adjust to changes in reimbursement and other industry regulations and trends, retain the services of key personnel, and other important risks and uncertainties referenced and discussed under the heading titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission. In addition, there is uncertainty about the spread of the Covid-19 virus and the impact it may have on the Company’s operations, the demand for the Company’s services, and economic activity in general.

The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not assume any obligations to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

SOURCE MTBC

Company Contact:

Bill Korn
Chief Financial Officer
MTBC, Inc.
[email protected]

Investor Contact:

Matt Kreps
Managing Director
Darrow Associates Investor Relations
[email protected]

Media Inquiries:

Mike Cuesta
Chief Marketing Officer
MTBC, Inc.
[email protected]

Hall of Famer and Former NBA and NCAA Champion Derek Anderson Joins Draganfly Board of Advisors

Anderson to help champion Draganfly’s Vital Intelligence technology into colleges and professional sports

Los Angeles, CA, Nov. 12, 2020 (GLOBE NEWSWIRE) — Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer and systems developer, today announced that Derek Anderson has joined as a member of the Board of Advisors.

Since retiring from the NBA, Derek Anderson founded the Stamina Foundation which provides educational programming and events which empower youth and young adults with resources and life skills. The Stamina Foundation has paved the way for over 100 under-privileged youth to attend college in a 20 year span.

Derek was drafted as the 13th pick in the 1997 NBA draft and became the first player signed to the Michael Jordan Brand and given his own signature shoe. With his first pay check from the NBA, he started his Foundation. In 2006, Derek won a World Title with the Miami Heat, becoming 1 of 13 players to win both an NCAA and NBA championship. He retired after an eleven-year NBA career in 2008. After retirement, he expanded his business life and opened two hotels in Turks & Caicos, his own film studio (Loyalty Media Group), and began writing novels and screenplays. In 2010, Derek produced and directed the documentary “The Untouchables of Kentucky.”

Cameron Chell, CEO of Draganfly, said: “We are excited and truly honoured to have Derek Anderson agree to join Draganfly’s outstanding Board of Advisors. Derek brings an incredible level of enthusiasm to our board coupled with a genuine understanding of the importance of our Vital Intelligence technology as an enabler in keeping schools open and ensuring that the lives of our youth continue as normal as possible through sports and other important activities.”

“I am honoured to have been appointed to Draganfly’s Board of Advisors,” said Derek Anderson. “I am looking forward to actively working with the Draganfly team to advocate for stronger health assessment measures across arenas and schools so that our athletes and youth can continue to move forward with their future.”

Draganfly has recently augmented its team with other key leaders, including the following:

  • Andrew H. Card, former White House Chief of Staff and U.S. Secretary of Transportation, joined the Company’s Board of Directors on November 7, 2019.
  • Julie Myers Wood, CEO of Guidepost Solutions and former Assistant Secretary of Homeland Security, joined the Company’s Board of Advisors on March 3, 2020.
  • Molly Wilkinson, Vice President of Regulatory Affairs at American Airlines and former Republican General Counsel for the U.S. Senate Committee on Homeland Security and Governmental Affairs, joined the Company’s Board of Advisors on March 12, 2020.
  • Dr. Jack Chow, former U.S. Ambassador and Assistant Director-General of the World Health Organization on HIV/AIDS, Tuberculosis and Malaria joined the Company’s Board of Advisors on April 8, 2020.
  • Captain Lawrence Vincent (USN, Ret.), current Executive Officer, Defence Counter- Intelligence Agency, and former Operations Center Director for Naval and Marine Corps Forces in Europe and Africa, joined the Company’s Board of Advisors on April 16, 2020.
  • John Mitnick, former General Counsel of the US Department of Homeland Security and Raytheon Senior Executive, the Company’s Board of Directors on June 11, 2020.

Exercise and Amendment of Existing Warrants

Draganfly is pleased to announce that it has received approximately $1.6 million in proceeds from the exercise of existing warrants that were issued on November 5, 2019 with an exercise price of
$0.50 per warrant (the “Existing Warrants“). Draganfly also announces that it has amended the terms of 9,602,624 Existing Warrants to extend the expiry date by an additional year to November 5, 2021, provided that the holders of the Existing Warrants exercise 25% of the Existing Warrants by May 5, 2021 and the remaining 50% of the Existing Warrants by November 5, 2021 (otherwise the Existing Warrants will expire at the applicable time).

About Draganfly

Draganfly Inc. (CSE: DFLY; OTCQB: DFLYF; FSE: 3U8) is the creator of quality, cutting-edge software and systems that revolutionize the way organizations can do business and service their stakeholders. Recognized as being at the forefront of technology for over 22 years, Draganfly is an award-winning, industry-leading manufacturer and technology developer serving the public safety, agriculture, industrial inspections, security, and mapping and surveying markets. Draganfly is a company driven by passion, ingenuity, and the need to provide efficient solutions and first- class services to its customers around the world with the goal of saving time, money, and lives.

For more information on Draganfly, please visit us at www.draganfly.com.
For additional investor information, visit https://www.thecse.com/en/listings/technology/draganfly-inc, https://www.otcmarkets.com/stock/DFLYF/overviewor https://www.boerse-frankfurt.de/aktie/draganfly-inc.

Media Contact Arian Hopkins
email: [email protected]

Company Contact
Email: [email protected]

Forward-Looking Statements

This release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out here in, including but not limited to: the potential impact of epidemics, pandemics or other public health crises, including the current outbreak of the novel coronavirus known as COVID-19 on the Company’s business, operations and financial condition, the successful integration of technology, the inherent risks involved in the general securities markets; uncertainties relating to the availability and costs of financing needed in the future; the inherent uncertainty of cost estimates and the potential for unexpected costs and expenses, currency fluctuations; regulatory restrictions, liability, competition, loss of key employees and other related risks and uncertainties disclosed under the heading “Risk Factors“ in the Company’s most recent filings filed with securities regulators in Canada on the SEDAR website at www.sedar.com. The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents managements’ best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.

Attachment

IMAC Holdings Reports Third Quarter 2020 Financial Results

Financial performance improves sequentially with record billable patient visits and highlights strong operational and fiscal management despite continued COVID-19 impact

BRENTWOOD, Tenn., Nov. 12, 2020 (GLOBE NEWSWIRE) — IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or the “Company”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announces its financial results for its third quarter ended September 30, 2020.

Third Quarter Highlights and Recent Developments:

  • Announced the opening of enrollment in early November in its Phase 1 clinical study of umbilical cord-derived mesenchymal stem cells for the treatment of bradykinesia due to Parkinson’s Disease
     
  • Announced the addition of three new highly qualified independent directors – Maurice “Mo” Evans, Michael Pruitt, and Cary Sucoff – to its board of directors
     
  • Sold its Lexington, Ky. property for $1.3 million in a sale-leaseback transaction
     
  • Reduced general and administrative expenses by 27% year-over-year and 20% quarter-over-quarter to $961,521 in the third quarter of 2020 with positive impacts from the realization of expense synergies from centralized purchasing, improved ordering, inventory control, and expense management, most notably from lower travel expenses given the coronavirus pandemic
     
  • Recognized record billable patient volume of 37,992 visits in the third quarter of 2020, up 8% year-over-year
     
  • Patient expenses declined 55% to $428,615 in the third quarter of 2020 from $950,517 in same period in 2019 due to improvements in supply management and a shift in service mix from knee care to spinal patients, who have a lower associated cost of therapy, reflecting behavioral adjustments associated with COVID-19-based activity restrictions
     
  • Wellness Membership subscribers increased 20% sequentially during the quarter to 762 members

“We are at an exciting time in the Company’s development, with the recent launch of its Phase 1 clinical trial for IMAC’s umbilical cord-derived mesenchymal stem cell treatment for bradykinesia due to Parkinson’s disease. This is a complement to IMAC’s evolution as a regenerative rehabilitation company. These proprietary advancements give IMAC the potential to dramatically improve the non-opioid treatment landscape for a variety of physical ailments and derive asset value beyond its brick and mortar locations. This focus, along with the addition of three deeply experienced, growth-oriented professionals to IMAC’s board of directors, should help IMAC capitalize on timely opportunities,” commented Jeffrey Ervin, IMAC’s Chief Executive Officer.

“While the COVID-19 pandemic has continued to negatively impact IMAC’s revenue on a year-over-year basis, the Company has been extremely diligent and focused on continuing what it began prior to the pandemic to ensure that it is wisely allocating capital, strategically reducing expenses, and prudently managing operations. All of this is being done with an eye toward continuing to expand both in the markets where IMAC has a foothold and in creating new and adjacent market opportunities through acquisition and partnerships. Even in this challenging environment, IMAC’s third quarter results exhibited a marked improvement from the second quarter of 2020 with net patient revenue of $3.5 million in the third quarter, up 35% sequentially from $2.6 million in the second quarter. Additionally, G&A costs decreased by 20 percent sequentially from the second quarter, which, when coupled with the sequential revenue increase, led to a 23% improvement in operating loss over the same period.

“Looking at how that translates to patient care, patient visits increased 44% quarter-over-quarter while patient expenses decreased 55%. IMAC’s patient service mix shifted in the quarter to a higher concentration of spine patients, rather than knee patients, which lowered both IMAC’s average charge per visit as well as its patient treatment expense, driving quarter-over-quarter improvement. Lastly, IMAC remains committed to improving its balance sheet and operations, reducing its notes payable in the quarter by approximately $1.2 million to a balance of $4.5 million, with nearly $1.7 million of this amount in the form of a Small Business Administration Paycheck Protection Program loan that we anticipate will achieve at least partial forgiveness” concluded Mr. Ervin.

Results of Operations for the Three and Nine Months Ended September 30, 2020

Net patient service revenues decreased 20% to $3.5 million for the three months ended September 30, 2020, compared to $4.4 million for the three months ended September 30, 2019. This decrease was due to the continued impact of COVID-19 and a change in the procedure mix. Patient service revenue decreased 14% to $9.4 million for the nine months ended September 30, 2020, compared to $10.9 million for the nine months ended September 30, 2019. This decrease is attributable to the IMAC’s acquisitions of clinics in Chicago and Florida in April 2019 and January 2020, respectively, along with the impacts of COVID-19.

The Company reported a net loss per share for the quarter ending September 30, 2020 of $0.12 vs. a loss per share of $0.19 for the comparable year-ago period. For the nine-month period ending September 30, 2020, the Company reported a net loss per share of $0.49 vs a loss per share of $0.68 for the nine months ended September 30, 2019.

About IMAC Holdings, Inc.

IMAC Holdings was created in March 2015 to expand on the footprint of the original IMAC Regeneration Center, which opened in Kentucky in August 2000. IMAC Regeneration Centers combine life science advancements with traditional medical care for movement-restricting diseases and conditions. IMAC owns or manages 15 outpatient clinics that provide regenerative, orthopedic, and minimally invasive procedures and therapies. It has partnered with several active and former professional athletes, opening two Ozzie Smith IMAC Regeneration Centers, two David Price IMAC Regeneration Centers, as well as Mike Ditka IMAC Regeneration Centers and a Tony Delk IMAC Regeneration Center. IMAC’s outpatient medical clinics emphasize its focus around treating sports and orthopedic injuries without surgery or opioids. More information about IMAC Holdings, Inc. is available at www.imacregeneration.com

Safe Harbor Statement

This press release contains forward-looking statements. These forward-looking statements, and terms such as “anticipate,” “expect,” “believe,” “may,” “will,” “should” or other comparable terms, are based largely on IMAC’s expectations and are subject to a number of risks and uncertainties, certain of which are beyond IMAC’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the skills and experience necessary to meet customers’ requirements, and its ability to protect its intellectual property. IMAC encourages you to review other factors that may affect its future results in its registration statement and in its other filings with the Securities and Exchange Commission. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this press release will in fact occur.

IMAC Press Contact:

Laura Fristoe
[email protected]

Investors:
Bret Shapiro
(516) 222-2560
[email protected]

IMAC HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

    September 30, 2020     December 31, 2019  

ASSETS
               
Current assets:                
Cash   $ 1,664,304     $ 373,689  
Accounts receivable, net     1,433,457       1,258,325  
Deferred compensation, current portion     241,946       312,258  
Other assets     452,741       633,303  
Total current assets     3,792,448       2,577,575  
                 
Property and equipment, net     1,861,879       3,692,009  
                 
Other assets:                
Goodwill     2,040,696       2,040,696  
Intangible assets, net     6,846,385       7,169,072  
Deferred equity costs     143,655       170,274  
Deferred compensation, net of current portion     310,006       549,563  
Security deposits     413,407       499,488  
Right of use asset     3,965,755       3,719,401  
Total other assets     13,719,904       14,148,494  
                 
Total assets   $ 19,374,231     $ 20,418,078  
                 

LIABILITIES AND STOCKHOLDERS’ EQUITY
               
                 
Current liabilities:                
Accounts payable and accrued expenses   $ 2,367,438     $ 2,909,666  
Patient deposits     373,678       189,691  
Notes payable, current portion, net of deferred loan costs     1,839,306       1,422,554  
Finance lease obligation, current portion     18,047       17,473  
Line of credit     79,961       79,961  
Liability to issue common stock, current portion     310,575       421,044  
Operating lease liability, current portion     1,051,964       1,025,247  
Total current liabilities     6,040,969       6,065,636  
                 
Long-term liabilities:                
Notes payable, net of current portion     2,671,333       2,109,065  
Finance lease obligation, net of current portion     52,957       66,565  
Liability to issue common stock, net of current portion     378,760       578,866  
Operating lease liability, net of current portion     3,723,398       3,660,654  
Other non-current liabilities     15,000        
                 
Total liabilities     12,882,417       12,480,786  
                 
Stockholders’ equity:                
Preferred stock – $0.001 par value, 5,000,000 authorized, nil issued and outstanding at September 30, 2020 and December 31, 2019, respectively            
Common stock – $0.001 par value, 30,000,000 authorized, 11,839,972 and 8,913,258 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively     11,834       8,907  
Additional paid-in capital     24,119,889       20,050,634  
Accumulated deficit     (15,235,941 )     (10,042,050 )
Non-controlling interest     (2,403,968 )     (2,080,199 )
Total stockholders’ equity     6,491,814       7,937,292  
                 
Total liabilities and stockholders’ equity   $ 19,374,231     $ 20,418,078  

IMAC HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

    Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
    2020     2019     2020     2019  
                         
Patient revenues, net   $ 3,477,841     $ 4,355,904     $ 9,359,490     $ 10,882,487  
Management fees                 12,487        
Total revenue     3,477,841       4,355,904       9,371,977       10,882,487  
                                 
Operating expenses:                                
Patient expenses     428,615       950,517       1,213,799       2,314,424  
Salaries and benefits     2,622,266       2,878,391       7,882,665       7,536,223  
Share-based compensation     108,377       112,959       311,406       288,298  
Advertising and marketing     234,694       317,800       650,861       1,014,144  
Grant funds                 (415,978 )      
General and administrative     961,521       1,311,315       3,406,116       3,718,506  
Depreciation and amortization     430,121       422,405       1,334,267       1,104,961  
Total operating expenses     4,785,594       5,993,387       14,383,136       15,976,556  
                                 
Operating loss     (1,307,753 )     (1,637,483 )     (5,011,159 )     (5,094,069 )
                                 
Other income (expense):                                
Interest income     6,028       120       6,067       125  
Other income (expenses)     6       (94 )     6       (15,384 )
Beneficial conversion interest expense                       (639,159 )
Gain (loss) on extinguishment of debt     9,783             (99,761 )      
Loss on disposal of assets     (39,047 )           (60,272 )      
Interest expense     (141,416 )     (74,456 )     (352,541 )     (190,337 )
Total other (expenses)     (164,646 )     (74,430 )     (506,501 )     (844,755 )
                                 
Net loss before income taxes     (1,472,399 )     (1,711,913 )     (5,517,660 )     (5,938,824 )
                                 
Income taxes                        
                                 
Net loss     (1,472,399 )     (1,711,913 )     (5,517,660 )     (5,938,824 )
                                 
Net loss attributable to the non-controlling interest     42,741       162,951       323,769       889,907  
                                 
Net loss attributable to IMAC Holdings, Inc.   $ (1,429,658 )   $ (1,548,962 )   $ (5,193,891 )   $ (5,048,917 )
                                 
Net loss per share attributable to common stockholders                                
Basic and diluted   $ (0.12 )   $ (0.19 )   $ (0.49 )   $ (0.68 )
                                 
Weighted average common shares outstanding                                
Basic and diluted     11,839,972       8,366,287       10,549,899       7,472,738  
     

IMAC HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

    Common Stock     Additional     Non-              
    Number of
Shares
    Par     Paid-In-
Capital
    Controlling
Interest
    Accumulated Deficit     Total  
                                     
Balance, December 31, 2018      4,533,623     $ 4,534     $ 1,233,966     $ (1,625,840 )   $ (3,544,820 )   $ (3,932,160 )
Common stock issued for initial public offering proceeds, net of related fees     850,000       850       3,503,314                   3,504,164  
Issuance of common stock in connection with convertible notes     449,217       449       2,245,636                   2,246,085  
Issuance of common stock in connection with acquisitions     1,410,183       1,410       7,247,798                   7,249,208  
Exercise of warrants     9,900       10       49,490                   49,500  
Net loss                       (431,223 )     (1,599,187 )     (2,030,410 )
Balance, March 31, 2019     7,252,923       7,253       14,280,204       (2,057,063 )     (5,144,007 )     7,086,387  
Issuance of common stock in connection with acquisitions     1,002,306       1,002       4,072,436                   4,073,438  
Exercise of warrants     61,569       62       307,783                   307,845  
Issuance of employee stock options                 16,216                   16,216  
Net loss                       (295,733 )     (1,900,768 )     (2,196,501 )
Balance, June 30, 2019     8,316,798       8,317       18,676,639       (2,352,796 )     (7,044,775 )     9,287,385  
Issuance of common stock     133,297       133       150,652                   150,785  
Issuance of employee stock options                 35,963                   35,963  
Net loss                       (162,951 )     (1,548,962 )     (1,711,913 )
Balance, September 30, 2019     8,450,095     $ 8,450     $ 18,863,254     $ (2,515,747 )   $ (8,593,737 )   $ 7,762,220  

    Common Stock     Additional     Non-              
    Number of
Shares
    Par     Paid-In-
Capital
    Controlling
Interest
    Accumulated Deficit     Total  
                                     
Balance, December 31, 2019     8,913,257     $ 8,907     $ 20,050,634     $ (2,080,199 )   $ (10,042,050 )   $ 7,937,292  
Issuance of common stock     1,095,840       1,096       1,376,122                   1,377,218  
Issuance of employee stock options                 38,359                   38,359  
Net loss                       (336,604 )     (1,733,545 )     (2,070,149 )
Balance, March 31, 2020     10,009,097       10,003       21,465,115       (2,416,803 )     (11,775,595 )     7,282,720  
Issuance of common stock     1,830,875       1,831       2,576,820                   2,578,651  
Issuance of employee stock options                 37,569                   37,569  
Net income (loss)                       55,576       (2,030,688 )     (1,975,112 )
Balance, June 30, 2020     11,839,972       11,834       24,079,504       (2,361,227 )     (13,806,283 )     7,923,828  
Issuance of employee stock options                 40,385                   40,385  
Net loss                       (42,741 )     (1,429,658 )     (1,472,399 )
Balance, September 30, 2020     11,839,972     $ 11,834     $ 24,119,889     $ (2,403,968 )   $ (15,235,941 )   $ 6,491,814  

 IMAC HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

    Nine Months Ended

September 30,
 
    2020     2019  
Cash flows from operating activities:                
Net loss   $ (5,517,660 )   $ (5,938,824 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Depreciation and amortization     1,334,267       1,104,961  
Beneficial conversion interest expense           639,159  
Share based compensation     311,406       288,298  
Loss on disposition of assets     1,959        
Non cash expense           150,785  
(Increase) decrease in operating assets:                
Accounts receivable, net     (154,292 )     64,046  
Other assets     251,976       (53,450 )
Security deposits     86,081       (59,966 )
Increase (decrease) in operating liabilities:                
Accounts payable and accrued expenses     (518,074 )     736,704  
Patient deposits     183,987       358,906  
Lease incentive obligation           (85,894 )
Net cash used in operating activities     (4,020,350 )     (2,795,275 )
                 
Cash flows from investing activities:                
Purchase of property and equipment     (52,626 )     (688,312 )
Purchase of license fee     (243,750 )      
Acquisition of IMAC Florida (Note 6)     (200,000 )      
Net cash used in investing activities     (496,376 )     (688,312 )
                 
Cash flows from financing activities:                
Proceeds from initial public offering, net of related fees           3,839,482  
Proceeds from warrants exercised           357,345  
Proceeds from issuance of common stock     3,736,613        
Proceeds from notes payable     2,891,520       212,800  
Payments on notes payable     (737,758 )     (86,958 )
Payments of debt issuance costs     (70,000 )      
Proceeds from line of credit           20,000  
Payments on line of credit           (300,000 )
Payments on finance lease obligation     (13,034 )     (12,487 )
Net cash provided by financing activities     5,807,341       4,030,182  
                 
Net increase in cash     1,290,615       546,595  
                 
Cash, beginning of period     373,689       194,316  
                 
Cash, end of period   $ 1,664,304     $ 740,911  
                 

Supplemental cash flow information:
               
Interest paid   $ 63,152     $ 97,147  
Taxes paid         $ 18,533  

Non cash financing and investing:
               
Debt discount notes payable   $ 115,000     $  
Debt payment by sale of property and equipment   $ 1,232,500     $  
Business acquisition via stock issuance   $     $ 3,771,978  

Upwork To Present at the Needham Virtual Internet Services Conference

Event to be Audio Webcast on the Upwork Investor Relations Website

SANTA CLARA, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — Upwork Inc. (Nasdaq: UPWK), the world’s largest work marketplace that connects businesses with independent talent, as measured by gross services volume (“GSV”), today announced that President and CEO, Hayden Brown, and Chief Financial Officer, Jeff McCombs, will participate in a fireside chat at the Needham Virtual Internet Services Conference. The event will take place on Monday, November 16, 2020 at 8:30a.m. PT/11:30a.m. ET.

An audiocast of the event will be available in the Events and Presentations section of Upwork’s Investor Relations website at investors.upwork.com. An audio webcast archive will be available following each event for approximately 90 days at investors.upwork.com. Please contact the respective financial institution hosting the conference for additional details. During the course of this event, Upwork may disclose material developments affecting its business and/or financial performance.

About Upwork

Upwork is the world’s largest work marketplace that connects businesses with independent talent, as measured by gross services volume (“GSV”). We serve everyone from one-person startups to 30% of the Fortune 100 with a powerful, trust-driven platform that enables companies and freelancers to work together in new ways that unlock their potential. Our talent community earned over $2 billion on Upwork in 2019 across more than 8,000 skills, including website & app development, creative & design, customer support, finance & accounting, consulting, and operations. Learn more at www.upwork.com and join us on LinkedIn, Twitter, and Facebook.

Upwork is a registered trademark of Upwork Inc. All other product and brand names may be trademarks or registered trademarks of their respective owners.

Denise Garcia
Investor Relations
[email protected]

Surna Reports Q3 2020 Results and Recent Sales Contracts


Announces $4.4 million in New Sales Contracts in Q3, among highest in Company history

Boulder, Colorado, Nov. 12, 2020 (GLOBE NEWSWIRE) — Surna Inc. (OTCQB: SRNA) announced today operating and financial results for the three and nine months ended September 30, 2020.

Financial Highlights

  As of September 30, 2020, our cash was $2,072,000, compared to cash of $922,000 as of December 31, 2019. Our working capital deficit was $1,793,000 as of September 30, 2020, compared to a working capital deficit of $1,437,00 as of December 31, 2019. Our continued focus on disciplined cash management has helped us weather the financial uncertainties of the current pandemic.
     
  Our Q3 2020 gross profit margin was 32.3% compared to 28.6% for Q3 2019, an increase of 3.6 percentage points.
     
  Our Q3 2020 revenue was $1,635,000, which represents a 70% decrease compared to Q3 2019 revenue of $5,524,000.
     
  For Q3 2020, our operating loss and net loss was $283,000 and $270,000, respectively. This compares to a Q3 2019 operating income and net income of $277,000 and $222,000, respectively.
     
  Our Q3 2020 adjusted net loss was $186,000, compared to a Q3 2019 adjusted net income of $365,000.

Previous Downsizing of Operations

As we noted in our 2019 Annual Report on Form 10-K, filed in March of this year, recent events in the national and global economies have had an adverse impact on our operations and financial condition, including constraints on capital availability for us and our customers and prospects who have commenced, or are contemplating, new and expanded cannabis cultivation facilities. Most recently, the response to this coronavirus pandemic by federal, state and local governments in the U.S. has resulted in significant market and business disruptions across many industries and affecting businesses of all sizes. This pandemic has also further tightened capital access for most businesses. The full extent to which COVID-19 will impact our business and financial results will depend on future developments, which are uncertain and cannot be predicted at this time.

Recent Sales Contracts and Stability of Operations

During the third quarter of 2020, we entered into new sales contracts totaling approximately $4.4 million, including our largest-ever single contract for $2.8 million, most of which we expect to be realized as revenue in 2020. This level of contract booking is among the highest for the Company in the last several years. To meet this new demand, we have restored our hourly workforce to full-time status and recalled those previously on furlough.

Despite this good news, the general economic conditions, government mandates about permitted work and working environments, and working capital constraints, all of which effect both our customers and us and our downsizing may have an adverse effect on our ability to effectively market our services, generate new customer orders, and contract implementation. If our customers or prospects are unable to continue operations or obtain project financing and we are unable to increase revenues or otherwise generate cash flows from operations, we will not be able to successfully execute on our various strategies and initiatives to grow our business. If these actions do not meet our expectations, or additional near-term capital is not available, we may not be able to continue our operations.

Product Development Initiatives

We have a sales and marketing program that generates many prospective customer relationships. However, our limited range of higher cost products, mostly chilled water systems, reduces the number of customer prospects who can afford to buy from us. In 2018 we started an aggressive effort to broaden our product and service offerings to provide a wider range of HVAC technical solutions (see chart in our Form 10-Q filed November 12, 2020). In 2018 we began to offer stamped mechanical plan sets and our first 4-pipe chilled water systems. In 2019 we broadened our engineering services to include full MEP (Mechanical, Electrical, and Plumbing) design services. We also began to offer our SentryIQ Controls System. And in 2020 we added new products to include: split system DX (direct expansion) with integrated dehumidification, packaged DX systems with modulating hot gas reheat, heat recovery chiller/boiler for 4-pipe systems, and we recently added our StrataAir™ racking airflow solution to address customer needs for multi-level cultivation facilities. These various systems provide solutions to answer a broader range of technical and cost constraints and we will continue to develop and offer new solutions to our customers’ problems, so that a broader group of growers can take advantage of our engineering expertise and capabilities. We believe these new products and services will increase our addressable market and increase sales, further leveraging our investment in sales and marketing.

The success of our product development initiative can be seen below, which documents the number of commercial-scale projects (over $100,000 sales) that have included one or more of our new products:

Year Percent Using New Products
2018 35%
2019 76%
2020 (through Q3): 100%

Tony McDonald, CEO, commented: “The third quarter of this year has seen a dramatic turnaround in Surna’s new project bookings from the first half of the year. Our view has been that cultivation construction projects were delayed and not abandoned as a result of uncertainty around the economic impact of the pandemic. And while we did experience one large and several smaller project cancellations in the second and third quarters, we have been optimistic that project orders would rebound, especially given the continued growth of retail product sales. Fortunately, we saw just that in the third quarter.”

About Surna Inc.

Surna Inc. (www.surna.com) designs, engineers and sells cultivation technologies for controlled environment agriculture including: (i) liquid-based process cooling systems and other climate control systems, (ii) air handling equipment and systems, (iii) a full-service engineering package for designing and engineering commercial scale thermodynamic systems specific to cannabis cultivation facilities, and (iv) automation and control devices, systems and technologies used for environmental, lighting and climate control. Our customers include commercial, state- and provincial-regulated cannabis growers in the U.S. and Canada as well as other international locations, including those growers building new facilities and those expanding or retrofitting existing facilities. Currently, our revenue stream is derived primarily from supplying our products, services and technologies to commercial indoor and hybrid sealed greenhouse facilities ranging from several thousand to more than 100,000 square feet.

Headquartered in Boulder, Colorado, we leverage our experience in this space to bring value-added climate control solutions to our customers that help improve their overall crop quality and yield, optimize energy and water efficiency, and satisfy the evolving state and local codes, permitting and regulatory requirements. Although our customers do, we neither produce nor sell cannabis.

Forward Looking Statements

This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect our current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release, including the factors set forth in “Risk Factors” set forth in our annual and quarterly reports filed with the Securities and Exchange Commission (“SEC”), and subsequent filings with the SEC. Please refer to our SEC filings for a more detailed discussion of the risks and uncertainties associated with our business, including but not limited to the risks and uncertainties associated with our business prospects and the prospects of our existing and prospective customers; the inherent uncertainty of product development; regulatory, legislative and judicial developments, especially those related to changes in, and the enforcement of, cannabis laws; increasing competitive pressures in our industry; and relationships with our customers and suppliers. Except as required by the federal securities laws, we undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise. The reference to Surna’s website has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.

Non-GAAP Financial Measures

To supplement our financial results on U.S. generally accepted accounting principles (“GAAP”) basis, we use non-GAAP measures including net bookings and backlog, as well as other significant non-cash expenses such as stock-based compensation and depreciation expenses. We believe these non-GAAP measures are helpful in understanding our past performance and are intended to aid in evaluating our potential future results. The presentation of these non-GAAP measures should be considered in addition to our GAAP results and are not intended to be considered in isolation or as a substitute for financial information prepared or presented in accordance with GAAP. We believe these non-GAAP financial measures reflect an additional way to view aspects of our operations that, when viewed with our GAAP results, provide a more complete understanding of factors and trends affecting our business.

Statement about Cannabis Markets

The use, possession, cultivation, and distribution of marijuana is prohibited by U.S. federal law for medical and recreational purposes. Although certain states have legalized medical and recreational cannabis, companies and individuals involved in the sector are still at risk of being prosecuted by federal authorities. Further, the landscape in the cannabis industry changes rapidly. This means that at any time the city, county, or state where cannabis is permitted can change the current laws and/or the federal government can supersede those laws and take prosecutorial action. Given the uncertain legal nature of the cannabis industry, it is imperative that investors understand that investments in the cannabis industry should be considered very high risk. A change in the current laws or enforcement policy can negatively affect the status and operation of our business, require additional fees, stricter operational guidelines and unanticipated shut-downs.

  Surna Marketing
  Jamie English
  Managing Director of Marketing
  [email protected]
  (303) 993-5271

Surna Inc.

Consolidated Balance Sheets

    September 30,     December 31,  
    2020     2019  
    (Unaudited)          
ASSETS                
Current Assets                
Cash and cash equivalents   $ 2,072,312     $ 922,177  
Accounts receivable (net of allowance for doubtful accounts of $164,823 and $151,673, respectively)     97,257       138,357  
Inventory, net     521,650       1,231,243  
Prepaid expenses and other     757,498       269,491  
Total Current Assets     3,448,717       2,561,268  
Noncurrent Assets                
Property and equipment, net     176,823       257,923  
Goodwill     631,064       631,064  
Intangible assets, net     7,371       11,930  
Deposits           51,000  
Operating lease right-of-use asset     392,263       534,133  
Total Noncurrent Assets     1,207,521       1,486,050  
                 
TOTAL ASSETS   $ 4,656,238     $ 4,047,318  
                 
LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)                
                 
CURRENT LIABILITIES                
Accounts payable and accrued liabilities   $ 1,397,770     $ 1,832,959  
Deferred revenue     3,489,302       1,444,472  
Accrued equity compensation     101,472       503,466  
Current portion of operating lease liability     253,392       217,843  
Total Current Liabilities     5,241,936       3,998,740  
                 
NONCURRENT LIABILITIES                
Note payable and accrued interest     556,444        
Other liabilities     41,396        
Operating lease liability, net of current portion     238,139       404,209  
Total Noncurrent Liabilities     835,979       404,209  
                 
TOTAL LIABILITIES     6,077,915       4,402,949  
                 
Commitments and Contingencies (Note 7)            
                 
SHAREHOLDERS’ EQUITY (DEFICIT)                
Preferred stock, $0.00001 par value; 150,000,000 shares authorized; 42,030,331 shares issued and outstanding     420       420  
Common stock, $0.00001 par value; 350,000,000 shares authorized; 236,526,638 and 228,216,638 shares issued and outstanding, respectively     2,366       2,283  
Additional paid in capital     26,082,733       25,326,593  
Accumulated deficit     (27,507,196 )     (25,684,927 )
Total Shareholders’ Equity (Deficit)     (1,421,677 )     (355,631 )
                 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)   $ 4,656,238     $ 4,047,318  

 

Surna Inc.

Consolidated Statements of Operations

(Unaudited)

    For the Three Months Ended September 30,     For the Nine Months Ended September 30,  
    2020     2019     2020     2019  
Revenue, net   $ 1,634,669     $ 5,524,105     $ 5,127,018     $ 11,505,728  
                                 
Cost of revenue     1,108,758       3,943,758       3,869,758       7,987,516  
                                 
Gross profit     525,911       1,580,347       1,257,260       3,518,212  
                                 
Operating expenses:                                
Advertising and marketing expenses     89,695       123,566       333,669       415,479  
Product development costs     84,433       98,145       304,229       326,659  
Selling, general and administrative expenses     634,447       1,081,294       2,453,976       3,284,485  
Total operating expenses     808,575       1,303,005       3,091,874       4,026,623  
                                 
Operating income (loss)     (282,664 )     277,342       (1,834,614 )     (508,411 )
                                 
Other (expense) income:                                
Other (expense) income, net     13,621       (55,319 )     29,018       (30,146 )
Interest expense     (1,396 )           (16,673 )      
Total other (expense) income     12,225       (55,319 )     12,345       (30,146 )
                                 
Income (loss) before provision for income taxes     (270,439 )     222,023       (1,822,269 )     (538,557 )
                                 
Income taxes                        
                                 
Net income (loss)   $ (270,439 )   $ 222,023     $ (1,822,269 )   $ (538,557 )
                                 
Income (loss) per common share – basic and dilutive   $ (0.00 )   $ 0.00     $ (0.01 )   $ (0.00 )
                                 
Weighted average number of common shares outstanding, basic     236,526,638       227,918,377       234,711,893       227,475,335  
                                 
Weighted average number of common shares outstanding, dilutive     236,526,638       237,028,377       234,711,893       227,475,335  



Surna Inc.


Consolidated Statements of Cash Flows

(Unaudited)

    For the Nine Months Ended
September 30,
 
    2020     2019  
Cash Flows From Operating Activities:                
Net loss   $ (1,822,269 )   $ (538,557 )
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:                
Depreciation and intangible asset amortization expense     90,867       129,723  
Share-based compensation     252,757       675,963  
Provision for doubtful accounts     13,150       43,130  
Provision for excess and obsolete inventory     (5,117 )     (213,556 )
Loss on disposal of assets     4,124       115,359  
                 
Changes in operating assets and liabilities:                
Accounts receivable     27,950       60,436  
Inventory     714,709       213,271  
Prepaid expenses and other     (488,007 )     (568,031 )
Operating lease right-of-use asset     62,350        
Accounts payable and accrued liabilities     (397,181 )     213,044  
Deferred revenue     2,044,830       1,633,195  
Operating lease liability, net           (13,856 )
Accrued equity compensation     101,472        
Net cash provided by operating activities     599,635       1,750,121  
                 
Cash Flows From Investing Activities                
Purchases of property and equipment     (3,500 )     (3,043 )
Net cash used in investing activities     (3,500 )     (3,043 )
                 
Cash Flows From Financing Activities                
Proceeds from issuance of note payable     554,000        
Net cash provided by financing activities     554,000        
                 
Net increase in cash     1,150,135       1,747,078  
Cash, beginning of period     922,177       253,387  
Cash, end of period   $ 2,072,312     $ 2,000,465  
                 
Non-cash investing and financing activities:                
Interest paid   $     $  
Income taxes paid   $     $